Myllylahti, Lasse
Pitkänen, Hanna
Magnani, Harry
Lassila, Riitta
Article History
Received: 28 October 2021
Accepted: 23 December 2021
First Online: 4 February 2022
Declarations
:
: Yes
: Yes
: Harry Magnani was involved with the clinical development of danaparoid from 1980 to 2000 and in retirement has provided consultant services to various MAHs including the current license holder Aspen Pharma. All other authors declare no competing interests.